ONCT News and Press, Oncternal Therapeutics Inc. From 10/11/19

Oncternal Therapeutics ( ONCT ) may be a good speculative biotech to look into. That's because it has been able to develop a monoclonal antibody, known as cirmtuzumab, which targets the ROR1 protein. The targeting of this ROR1 protein allows cirmtuzumab to be explored in a couple of other comb...

Cirmtuzumab combination demonstrated clinical activity with complete responses in mantle cell lymphoma Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for ...

Sustained objective response reported for patient with challenging pediatric cancer Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Paul A. Meyers, M.D., Chief, Pediatri...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, P...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., a...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a tumultuous week, dipping from 3,330.51 points on Monday (August 19) to 3,257.94 points at 12:22 p.m. EDT on Friday (August 23). On Monday, Nabriva (NASDAQ: NBRV ) notched its first approval from the US Food and Drug Administration (F...

Gainers : DPW Holdings, Inc. (NYSEMKT: DPW ) +217% . Yuma Energy (NYSEMKT: YUMA ) +210% . DryShips (NASDAQ: DRYS ) +35%.  TrovaGene (NASDAQ: TROV ) +32% . Qiwi (NASDAQ: QIWI ) +22% . Houston Wire & Cable (NASDAQ: HWCC ) +22%.  China Green Agriculture (NYSE: CGA ) +21%....

Oncternal Therapeutics, Inc. (ONCT) Q2 2019 Results Earnings Conference Call August 08, 2019, 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President and CEO Conference Call Participants Hartaj Singh - Oppenheimer Kumar Raja -...

Oncternal Therapeutics (NASDAQ: ONCT ): Q2 GAAP EPS of -$3.38. More news on: Oncternal Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports opening Phase 2 Two product candidates moving forward in clinical trials Conference c...